Hannover, 24 August 2016. Rodos Biotarget GmbH is pleased about its membership in the Deutsche Börse Venture Network (DBVN). Access to the non-public network is based on a qualification process; several criteria must be met in order to join the network. The Venture Network is a platform designed to bring classified high-growth companies and international investors from the categories PE/VC, Family Office, High Net Worth Individuals (HNWI) and Public Equity together and create an environment for effective growth financing.
- Current Clinical Projects
- Who We Are